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Antimicrobial peptides (AMPs) expressed by epithe-
lial and immune cells are largely described for the de-
fense against invading microorganisms. Recently,
their immunomodulatory functions have been high-
lighted in various contexts. However how AMPs ex-
pressedbynon-immunecellsmight influenceautoim-
mune responses in peripheral tissues, such as the
pancreas, is unknown. Here, we found that insulin-
secreting b-cells produced the cathelicidin related
antimicrobial peptide (CRAMP) and that this produc-
tion was defective in non-obese diabetic (NOD)
mice. CRAMP administrated to prediabetic NOD
mice induced regulatory immune cells in the pancre-
atic islets, dampening the incidence of autoimmune
diabetes. Additional investigation revealed that the
production of CRAMP by b-cells was controlled by
short-chain fatty acids produced by the gut micro-
biota. Accordingly, gut microbiota manipulations in
NODmicemodulatedCRAMPproduction and inflam-
mation in the pancreatic islets, revealing that the gut
microbiota directly shape the pancreatic immune
environment andautoimmunediabetesdevelopment.
INTRODUCTION
Antimicrobial peptides (AMPs) are evolutionarily conserved pep-
tides found in almost all plants and animals. In mammals, they
are expressed by epithelial cells under steady-state conditions
and by infiltrating immune cells during inflammation (Gallo and
Hooper, 2012). AMPs are cationic polypeptides with the ability
to kill microorganisms by disrupting the integrity of their mem-
brane (Zasloff, 2002). Apart from their antimicrobial activity,304 Immunity 43, 304–317, August 18, 2015 ª2015 Elsevier Inc.AMPs have many functions in immunity, causing either pro-
inflammatory or anti-inflammatory effects according to the
model being investigated (Mansour et al., 2014). Among AMPs,
the role of the cathelicidins (human LL-37 and mouse CRAMP)
has been particularly documented in autoimmune diseases
such as atherosclerosis, small-vessel vasculitis, systemic lupus
erythematous, and psoriasis (Do¨ring et al., 2012; Kessenbrock
et al., 2009; Lande et al., 2011; Lande et al., 2007). One common
cause of these diseases is an excessive production of cathelici-
din by neutrophils, then forming complexes with self-nucleic
acids. These immune complexes target plasmacytoid dendritic
cells (pDCs) via TLR7 and TLR9 and induce a deleterious pro-
duction of type I interferon (IFN) (Kahlenberg and Kaplan,
2013). We have also highlighted that the same mechanism oc-
curs during the initiation of autoimmune diabetes in young
non-obese diabetic (NOD) mice (Diana et al., 2013). Indeed,
around the age of weaning, neutrophils transiently infiltrate the
pancreas and produce cathelicidins activating IFN-a-secreting
pDCs. However, the concentration of cathelicidins has been
shown to be reduced in the serum of patients with autoimmune
type 1 diabetes (T1D) compared with healthy subjects suggest-
ing an additional role of cathelicidins in T1D (Brauner et al., 2014).
Regarding the various potential source of cathelicidins in periph-
eral tissues (non-immune versus immune cells) and the opposing
immunomodulatory roles of cathelicidins (pro- versus anti-in-
flammatory), we addressed the question of whether cathelicidins
are produced by non-immune cells in the pancreas andmight in-
fluence the pancreatic immune environment in the context of
autoimmune diabetes in NOD mice.RESULTS
CRAMP Is Secreted in Pancreatic Islets and Its
Secretion Is Faulty in Female NOD Mice
To address whether the cathelicidin CRAMP was expressed in
pancreatic islets, we evaluated by ELISA the ex vivo secretion
Figure 1. CRAMP Is Secreted in Pancreatic
Islets and Its Secretion Is Faulty in Female
NOD Mice
(A‒D) Pancreatic islets from 8-week-oldmicewere
cultured overnight before CRAMP measurement
in the supernatant by ELISA (A, B, D) or Western
blot (C). Data are the median ± interquartile range
(A, B, D) or are representative (C) from five or six
independent experiments with two pooled mice
per group in each experiment.
(E) Islet cells were isolated, surface stained for
CD45, and intracellularly stained for insulin and
CRAMP, and analyzed by flow cytometry. Data are
the frequency and absolute number of positive
cells among the CD45‒ population and are repre-
sentative or the median ± interquartile range from
five independent experiments with two pooled
mice per group in each experiment.
(F and G) Isolated islets frommale NODmice (F) or
male healthy subject (G) were cytospinned, fixed,
and intracellularly stained for insulin (green),
glucagon (blue), CRAMP or LL-37 (red), and DNA
(gray). Data are representative from eight inde-
pendent experiments. **p < 0.01, ***p < 0.001.of CRAMP by islets isolated from 8-week-old female NOD,
BALB/c, and C57BL/6 mice. CRAMP was detected in the super-
natant of short-term cultured islets from all mouse strains
analyzed. However, its secretion was unexpectedly lower in
the NOD strain compared to the non-autoimmune strains (Fig-
ure 1A). The production of CRAMP was also lower in the islets
from female NOD mice compared to their male counterparts
(Figure 1B), suggesting a role for CRAMP in diabetes develop-
ment since male NOD mice develop a reduced incidence of
the disease. By Western blot, we observed that both the cyto-
plasmic pro-form (18KDa) and the secreted mature form
(5KDa) of CRAMP were produced by the islets of male and fe-
male NODmice (Figure 1C). We observed a similar ratio between
the pro- and themature forms inmale and femalemice excluding
a defect in the post-translational processing of the peptide in fe-
male NOD mice (Figure 1C).
CRAMP Is Expressed by Endocrine Cells in Mouse and
Human Pancreatic Islets
As cathelicidins have been shown to be produced by both im-
mune and non-immune cells in the intestine or the skin (GalloImmunity 43, 304–317and Hooper, 2012), we investigated the
cellular source of CRAMP in the pancre-
atic islets of 8-week-old prediabetic
NOD mice. We have previously identified
neutrophils as a source of CRAMP in the
islets of young NOD mice; however, neu-
trophils infiltrated the islets only tran-
siently around weaning period (Diana
et al., 2013). We also excluded a role for
infiltrating lymphoid cells since islets
from WT and lymphoid cell-deficient
scid NOD mice secreted similar amount
of CRAMP (Figure 1D). By flow cytometry,
we observed that the CD45+ infiltratingimmune cells did not express CRAMP in adult NOD mice, while
the CD45 non-immune cells did (Figure S1A). Among the non-
immune cells, insulin+ b-cells expressed CRAMP together with
insulin cells, and the frequency and number of CRAMP+CD45
cells in the islets was lower in NOD mice compared to the
non-autoimmune mice (Figure 1E). By microscopy, we further
observed that CRAMP co-localized with both glucagon- and in-
sulin-producing cells, supporting that both a- and b-cells consti-
tutively produced CRAMP in the mouse adult islets (Figure 1F).
LL-37, the human ortholog of CRAMP, was also expressed by
a- and b-cells in human islets from healthy donors (Figure 1G).
We failed to detect CRAMP expression by a- or b-cells in
4-week-old mice regardless the strain analyzed (Figure S1C).
These data suggested that in the NOD mice CRAMP was
sequentially produced in the islets, first by neutrophils in young
mice (Diana et al., 2013) and then by endocrine cells in adult
mice. Moreover, ex vivo, we observed that cathelicidin colocal-
ized with citrulline in activated neutrophils while we failed to
detect citrulline expression by b-cells (Figure S1D). As citrullina-
tion alters the immunomodudatory roles of cathelicidin (Kilsga˚rd
et al., 2012; Koziel et al., 2014), we hypothesized that CRAMP, August 18, 2015 ª2015 Elsevier Inc. 305
Figure 2. CRAMPIsProtectiveagainstAuto-
immune Diabetes in Adult NOD Mice
(A) Pancreatic islets were isolated from female
NOD mice treated with CRAMP, scrambled
CRAMP (sCRAMP), or vehicle (day 10). Cells were
stimulated with IGRP206–214-loaded DCs, before
staining for TCR-b, CD8, and intracellular IFN-g.
Data are the frequency of IFN-g+ cells among
CD8+ T cell population and are representative or
the median ± interquartile range from four inde-
pendent experiments with two independent mice
per group in each experiment.
(B) Female NOD mice were treated twice a week
with CRAMP and incidence of diabetes was fol-
lowed, n = 12 mice per group.
(C) C57BL/6 WT or Cnlp‒/‒ littermate mice were
treated with multiple low-dose streptozotocin and
blood glucose level was followed (day 0: day of the
first injection). Data are the median ± interquartile
range with 8 independent mice per group. Dia-
betes was diagnosed in mice with blood glucose
level > 200 mg dl1.
(D) Immune cell populations in the pancreatic
infiltrate from female NOD mice treated with
CRAMP or vehicle (day 2) were determined by flow
cytometry. Data are the frequency of gated cells
(CD19+ B cell, TCRb+ T cell, F4/80 CD11b+
CD11c+ DC, and F4/80+ CD11b+ macrophage)
among the CD45+ population or the absolute
number of cells per mouse. Data are representa-
tive or are the median ± interquartile range from six
independent experiments with two pooled mice
per group in each experiment. *p < 0.05, **p < 0.01,
***p < 0.001.produced by b-cells might have different roles on the pancreatic
immune environment than CRAMP from neutrophils. Collec-
tively, these data showed that endocrine cells produced CRAMP
in the islets of adult mice, but this production was faulty in female
NOD mice. These data prompted us to further investigate the
immunomodulatory role of CRAMP in adult NOD mice.
CRAMP Is Protective against Autoimmune Diabetes in
Adult NOD Mice
As CRAMP production was defective in the pancreatic islets of
female adult NODmice, we investigated the effect of CRAMP in-
jection on diabetes development in these mice. Intraperitoneal
administration of CRAMP but not of scrambled CRAMP
(sCRAMP) reduced the frequency of pancreatic IFN-g+CD8+
T cells specific of the b-cell antigen islet-specific glucose-6-
phosphatase catalytic subunit related protein (IGRP)206–214 and
dampened the incidence of autoimmune diabetes (Figures 2A
and 2B). To determine the impact of CRAMP-deficiency on auto-
immune diabetes development, we followed the development of
multiple low-dose streptozotocin- (MLD-STZ)-induced diabetes
in the CRAMP-deficient Cnlp/ and WT C57BL/6 mice (Nizet
et al., 2001). We observed an accelerated incidence of diabetes
in the CRAMP-deficient mice compared to WT mice (Figure 2C).
CRAMP expression was not detected in the infiltrating immune306 Immunity 43, 304–317, August 18, 2015 ª2015 Elsevier Inc.cells from MLD-STZ-treated C57BL/6 mice excluding a role of
CRAMP from these cells in MLD-STZ-induced diabetes (Fig-
ure S1B). To decipher whether CRAMP regulates the diabeto-
genic immune response, we analyzed the pancreatic immune
infiltrate in CRAMP-treated female NOD mice. Two days after
treatment, we observed a reduction in the total number of
infiltrating immune cells and particularly a decreased number
of B cells, T cells, and conventional dendritic cells (cDCs) in
CRAMP-treated but not sCRAMP-treated NOD mice (Figures
2D and S2A). In contrast, the frequency of macrophages
increased, while their total number remained unchanged. No
difference was observed in the pancreatic lymph nodes (PLN)
or the spleen except for an increased frequency and number
of medullary macrophages in the PLN (Figures S2B and S2C),
supporting a pancreas-specific effect of CRAMP treatment.
Together these data supported a protective effect of CRAMP
treatment against autoimmune diabetes by altering the pancre-
atic immune infiltrate in adult NOD mice.
CRAMP Induces a Phenotypic Switch in Pancreatic
Macrophages
As the number of pancreatic macrophages remained similar in
CRAMP-treated NOD mice, we evaluated how CRAMP might
alter their phenotype. Macrophages play a crucial role in
diabetes development through the induction of pancreatic
inflammation (Calderon et al., 2008), and the transfer of regula-
tory macrophages prevents diabetes in female NODmice (Parsa
et al., 2012). We observed that CRAMP treatment in female NOD
mice rapidly decreased the frequency and number of pancreatic
inflammatory macrophages (F4/80+CD11c+CD206), while the
frequency and number of regulatory macrophages (F4/80+
CD11cCD206+) were enhanced as shown by a reduced ratio
of inflammatory/regulatory macrophages (Figure 3A). This effect
was dose-dependent (Figure S3A), remained observed 7 days
after treatment (Figure S3B), and also observed with the human
cathelicidin LL-37, but not with the scrambled mouse or human
cathelicidins (Figure S3C). In order to compare the phenotype of
pancreatic macrophages between autoimmune and non-auto-
immune mice, we injected STZ that induces a rapid recruitment
ofmacrophages into the islets of bothmouse strains (Diana et al.,
2013). While STZ maintained a high ratio of inflammatory/
regulatory macrophages in female NOD mice, it resulted in
the recruitment of regulatory macrophages into the islets of
non-autoimmune strains (Figure 3A). Conversely, STZ-injection
in CRAMP-deficient C57BL/6 mice resulted in the recruitment
of inflammatory macrophages, confirming a role of CRAMP
in governing the phenotype of pancreatic macrophages (Fig-
ure 3B). Functionally, CRAMP-induced pancreatic macrophages
harbored a low expression of the inflammatory cytokines tumor
necrosis factor-a (TNF-a) and interleukin-12 (IL-12), while a
high expression of the regulatory cytokines IL-4 and active trans-
forming growth factor-b (TGF-b) (LAP) was evident (Figures 3C
and S3D). A similar phenotype was observed in the PLN, but
not in the spleen, supporting a pancreas-specific effect of
CRAMP (Figure S4). In addition, as described for tolerogenic
gut-associated myeloid cells, CRAMP-induced pancreatic mac-
rophages exhibited a high aldehyde dehydrogenase (ALDH)
activity reflecting retinoic acid (RA) production (Guilliams et al.,
2010) (Figure 3D).
CRAMP Regulates the Pi3K Pathway in Pancreatic
Macrophages
Next, we attempted to determine through which receptor
CRAMP exerted its regulatory effect on pancreatic macro-
phages. In adult NOD mice, nearly all the pancreatic macro-
phages expressed the epidermal growth factor receptor
(EGFR) contrary to DCs or T cells (Figure 4A). By utilizing specific
inhibitors (AG1478, A438079, and PB10) against known surface-
receptors for cathelicidin (EGFR, P2X7R, and FPR2, respec-
tively), we determined that EGFR was required for the
immunoregulatory effect of CRAMP on pancreatic macrophages
(Figure 4B). However, as we did not observe a complete rever-
sion of the effect of CRAMP after EGFR blockade, we cannot
exclude the involvement of other receptors. Next we determined
the molecular pathway regulated by CRAMP in pancreatic mac-
rophages, by analyzing the expression of SHIP1, a SH2-contain-
ing inositol-50-phosphatase critical in macrophage programming
via the regulation of the phosphoinositide 3-kinase (Pi3K)
pathway (Parsa et al., 2006). Twelve hours after CRAMP treat-
ment, SHIP1 expression in pancreatic macrophages increased
(Figure 4C), and the blockade of SHIP-1 with 3 a-aminocholes-
tane (3AC) (Brooks et al., 2010) prevented the induction of
regulatory macrophages by CRAMP (Figure 4D); both datasupporting that CRAMP induced regulatory macrophages via
SHIP1 induction. Accordingly, the phosphorylation of Akt and
NFkBp65, two downstream key molecules of the Pi3K pathway
inducing pro-inflammatory cytokine gene expression in macro-
phages (Zhou et al., 2014), was reduced in CRAMP-induced
pancreatic macrophages compared with macrophages from un-
treated NODmice (Figure 4E). Together, these results supported
that CRAMP regulated pancreatic inflammatory macrophages
via SHIP-1 induction regulating the Pi3K pathway.
CRAMP Induces Pancreatic Regulatory Dendritic Cells
CDCs are key players in autoimmune diabetes pathogenesis,
transporting b-cell antigens from the pancreatic islets to the
draining lymph nodes and presenting these self-antigens to au-
toreactive T cells (Ganguly et al., 2013). We observed that
CRAMP treatment of adult NODmice induces pancreatic regula-
tory cDCs characterized by low expression of costimulatory
markers (Figure 5A) and a regulatory cytokine profile with a low
level of IL-12, a high level of active TGF-b (Figure 5B), and a
high ALDH activity (Figure 3E). CDCs with a regulatory cytokine
profile were also observed in the PLN, but not in the spleen, of
CRAMP-treated NOD mice (Figure S4). However, increased
ALDH activity in cDCs and macrophages was observed only in
the islets of CRAMP-treated NOD mice (Figure S4). Together,
these data supported that CRAMP induced regulatory cDCs in
the pancreatic islets of adult prediabetic NOD mice.
CRAMP Generates Pancreatic Regulatory T (Treg) Cells
Both regulatory macrophages and cDCs have the potential to
induce Treg cells necessary for long-term protection against
autoimmune diabetes (Tang and Bluestone, 2008). Eight days
after CRAMP treatment, we observed an increased frequency
and number of both Foxp3+ Treg cells and IL-10-producing Tr1
cells in the islets, but not in the PLN or the spleen, of CRAMP-
treated female NOD mice (Figures 5C and S5). CRAMP also
stimulated the expression of regulatory molecules (TGF-b and
CD103) by Treg cells in the islets, but not in the PLN (Figures
5D and S6A). CRAMP-induced pancreatic Treg cells expressed
low amounts of neuropilin compared with Treg from vehicle- or
sCRAMP-treated NOD mice supporting that these Treg cells
originated from the conversion of naive T cells into inducible
Treg cells (Yadav et al., 2012) (Figure S6B). This result was
confirmed in vitro using purified pancreatic myeloid cells
(CD11b+ cells) cultured with monoclonal naive autoreactive
T cells devoid of Treg cells (CD62L+CD25‒CD4+ T cells) isolated
from the spleen of BDC2.5 TCR transgenic NOD mice. We
observed that myeloid cells from CRAMP-treated NOD mice
induced a higher number of Treg cells compared to their
counterparts from vehicle-treated NOD mice (Figure 5E).
Accordingly with the high ALDH activity of CRAMP-induced
myeloid cells (Figures 3D and 3E), this induction of Treg cells
was dependent on RA as revealed by the use of the RA-receptor
inhibitor LE135 (Figure 5E). Likely due to their inability to
produce RA, myeloid cells from the PLN or the spleen of
CRAMP-treated NOD mice failed to induce Treg cells (Fig-
ure S6C). Finally, using neutralizing anti-CD25 antibody, we
observed that CRAMP treatment in prediabetic NOD mice was
no more protective against diabetes in absence of functional
Treg cells (Figure S6D). Together, our data demonstrated thatImmunity 43, 304–317, August 18, 2015 ª2015 Elsevier Inc. 307
Figure 3. CRAMP Induces a Phenotypic Switch in Pancreatic Macrophages
(A and B) Macrophage sub-populations in the pancreatic infiltrate from female 8-week-old mice treated with CRAMP (day 2) and/or with streptozotocin (day 1).
Data show the ratio between the frequency of inflammatory and regulatory macrophages. Data are representative or are themedian ± interquartile range from five
independent experiments with one or two independent mice per group in each experiment.
(C–E) Cytokine production and ALDH activity in pancreatic macrophages were analyzed in female NOD mice treated with CRAMP or vehicle (day 2). Islet cells
were isolated, stimulated with LPS for 4 hr, and stained for CD45, CD11b, F4/80, and LAP; fixed and stained for TNF-a, IL-12, and IL-4 (C) or cells were isolated,
stained for ALDH activity, and then stained for the surface markers (D and E). Data shown were obtained after gating on macrophages (F4/80+ CD11b+) in (D) or
dendritic cells ((F4/80 CD11b+ CD11c+) in (E). Data are representative or are the median ± interquartile range from five or six independent experiments with two
pooled mice per group in each experiment. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 4. CRAMP Regulates the Pi3K Pathway in Pancreatic Macrophages
(A) Pancreatic macrophages expressed EGFR. Islets cells were isolated from 8-week-old female NOD mice and stained for CD45, CD11c, CD11b, F4/80, and
EGFR. Data show the frequency of EGFR+ cells in each population and are representative of three independent experiments with two pooled mice per group in
each experiment.
(B) Macrophage sub-populations in the pancreatic infiltrate from female NOD mice treated with CRAMP and with various CRAMP-receptor inhibitors (AG1478,
A438079, and PB10 for EGFR, P2X7R, and FPR2, respectively) (day 2). Data are representative or are the median ± interquartile range from five independent
experiments with two pooled mice per group in each experiment.
(C and E) Expression of SHIP1, p-Akt, and p-NFkBp65 in the macrophage population from the islets of female NOD mice treated with CRAMP (day 1). Islet cells
were isolated and stained for CD45, CD11b, F4/80, and then for SHIP1, p-Akt, and p-NFkBp65. Data are representative and themedian ± interquartile range from
three independent experiments with two independent mice per group in each experiment.
(D) Macrophage sub-populations in the pancreatic infiltrate from female NOD mice treated with CRAMP and with the SHIP-1 inhibitor 3AC (day 2). Data are
representative or are the median ± interquartile range from four independent experiments. *p < 0.05, **p < 0.01.
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Figure 5. CRAMP Induces Regulatory Dendritic Cells and T Cells in the Pancreatic Islets
(A) Surface phenotype of cDCs from the pancreatic islets of female NOD mice treated with CRAMP or vehicle (day 2) was determined by flow cytometry. Data
shownwere obtained after gating on dendritic cells (F4/80CD11b+ CD11c+). Data are representative and themedian ± interquartile range from five independent
experiments with two pooled mice per group in each experiment.
(legend continued on next page)
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CRAMP regulated the pancreatic immune environment in predi-
abetic NOD mice, inducing myeloid and lymphoid regulatory
cells preventing autoimmune diabetes.
CRAMP Production by b-cells Is Controlled by
Short-Chain Fatty Acids
Finally, we aimed to determine why CRAMPproduction by endo-
crine cells was defective in female NOD mice. In mammals,
short-chain fatty acids (SCFAs), produced by specific gut bacte-
ria, was demonstrated to induce cathelicidin expression in colo-
nocytes, lung epithelial cells, and gastrointestinal cells (Kida
et al., 2006; Schauber et al., 2004; Schauber et al., 2003). Conse-
quently, we hypothesized that the reduced pancreatic CRAMP
production in female NOD mice might be due to a lack of
endogenous stimulation of endocrine cells by SCFAs. By GC-
MS, we observed that the amount of SCFAs, and particularly
of butyrate, in the feces and the blood of female NOD mice
were lower than in the male NOD mice or female BALB/c or
C57BL/6 mice (Figure 6A and S7A). While butyrate was not
detectable in the islets from untreated mice, after intraperitoneal
(i.p.) injection of butyrate, butyrate concentration increased
in the islets and the blood but remained lower in the female
NOD mice than in the other mice (Figure S7A). Injection of buty-
rate to female NOD mice increased pancreatic CRAMP produc-
tion in a dose-dependent manner (Figures 6B and S7B) and
addition of butyrate or other SCFAs to islet culture also increased
CRAMP production, supporting a direct effect of SCFAs on
endocrine cells (Figures 6C and 6D). The G protein-coupled re-
ceptors (GPR)43 and GPR41, two receptors for SCFAs (Brown
et al., 2003), have been described to be expressed by b-cells
(Regard et al., 2007). Adding pertussis toxin prior to the addition
of SCFAs to islet culture, we confirmed that the induction of
CRAMP by SCFAs required functional GPRs (Figure 6D).
According to its stimulatory effect on CRAMP production, we
showed that butyrate mimicked the immunoregulatory effects
of CRAMP in the islets, decreasing the ratio of inflammatory/reg-
ulatory macrophages and increasing the frequency of ALDH+
DCs and Treg cells (Figures 6E–6G). The injection of butyrate
to SZT-treated CRAMP-deficient C57BL/6 mice failed to in-
crease the frequency of pancreatic regulatory macrophages,
supporting that the effect of butyrate on pancreatic macro-
phages was mediated via CRAMP induction (Figure S7C).
Finally, butyrate treatment of prediabetic NOD mice dampened
the frequency of pancreatic diabetogenic IFN-g+CD8+ T cells
and reduced the incidence of diabetes (Figures 6H and 6I). These
data supported that CRAMP production by b-cells is controlled
by SCFAs via GPRs and such pathway is defective in the female
NOD mice.(B) Cytokine by pancreatic cDCs were analyzed in female NOD mice treated with
stained. Data shown were obtained after gating on dendritic cell (F4/80 CD11b+
five or six independent experiments with two pooled mice per group in each exp
(C‒E) Regulatory T cells were analyzed in the islets from female NOD mice trea
CD103, and LAP, fixed, and then stained for Foxp3. Results show the frequency an
results are the frequency of the gated cells among the CD45+ Foxp3+ CD4+ T cel
from three independent experiments with two or three independentmice per group
NOD mice induce Treg cells in vitro. Myeloid cells (CD11b+) were isolated from t
3 days with naive BDC2.5 T cells with the presence of TGF-b and with the presenc
fixed, and then stained for Foxp3. Data show the number and frequency of Treg
quartile range from six independent experiments with four pooled mice per grouGut Microbiota Modulates CRAMP Production in the
Pancreatic Islets
Because SCFAs are produced by specific gut bacteria during
dietary fibers fermentation, we addressed the role of the gut
microbiota in the control of pancreatic CRAMP production. We
treated male NOD mice per os with broad-spectrum antibiotics
(ABX) to deplete these mice of their gut microbiota, and 10 days
after treatment, we observed that pancreatic CRAMPproduction
decreased (Figure 7A). Next, we transferred gut microbiota from
male NOD mice or from female BALB/c or C57BL/6 mice to fe-
male NOD mice, and 10 days after fecal transfer, we observed
that pancreatic CRAMP production increased in grafted female
NOD mice (Figure 7A). Accordingly with the immunoregulatory
role of CRAMP, ABX treatment of male NOD mice increased the
inflammatory/regulatory macrophage ratio in the islets, while
gutmicrobiota transfer frommale to femaleNODmicedecreased
this ratio in female NOD mice (Figure 7B). The pro-inflammatory
effect of ABX treatment in male NODmice was reversed by sub-
sequent CRAMP treatment, supporting that the gut microbiota
controlled thephenotypeof pancreaticmacrophagesviaCRAMP
induction (Figure 7C). As expected, ABX treatment increased the
incidence of diabetes in male NOD mice, while gut microbiota
transfer from male to female NOD mice reduced the incidence
of diabetes (Figures 7D and 7E). Together, our results supported
that gut microbiota modulated the pancreatic immune environ-
ment via SCFAs and CRAMP induction and thus controlled the
development of autoimmune diabetes.
DISCUSSION
Our study demonstrates that the gut microbiota via SCFAs con-
trols the production of the antimicrobial peptide CRAMP by the
pancreatic endocrine cells in adult mice. CRAMP harbors posi-
tive immuno-regulatory effect on pancreatic macrophages and
cDCs maintaining immune homeostasis in this tissue via Treg
cell induction. Thus, in female NODmice, a defective production
of SCFAs resulted in low amounts of pancreatic CRAMP, an un-
opposed pancreatic inflammation, and the development of auto-
immune diabetes.
The role of AMPs, and more specifically of cathelicidins, in im-
munity appears to be complex with both anti-inflammatory and
pro-inflammatory properties (Hilchie et al., 2013). Cathelicidins
are directly chemotactic for various innate immune cells such
as neutrophils, macrophages, or cDCs and also promote the
secretion of chemokines by epithelial cells (Oppenheim and
Yang, 2005). Cathelicidins have been shown to suppress the
pro-inflammatory activity of TLR ligands in macrophages via
various mechanisms: ligand sequestration by binding to LPSCRAMP or vehicle (day 2). Islet cells were isolated, stimulated with LPS, and
CD11c+). Data are representative or are the median ± interquartile range from
eriment.
ted with CRAMP or vehicle (day 8). Cells were stained for CD45, TCRb, CD4,
d absolute number of Treg cells (C, Foxp3+) among the CD4 T cell population or
l population (D). Data are representative or are the median ± interquartile range
in each experiment. (E) Pancreaticmyeloid cells isolated fromCRAMP-treated
he islets of female NOD mice treated with CRAMP or vehicle and cultured for
e or not of the RA inhibitor LE135. Then cells were stained for TCR-b and CD4,
cells (Foxp3+) among the CD4 T cell population. Data are the median ± inter-
p in each experiment. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 6. CRAMP Production by b-Cells Is Controlled by Short-Chain Fatty Acids
(A) Concentration of SCFAs in the feces of 8-week-old female and male NOD, BALB/c, and C57BL/6 mice was performed by GC-MS. Data are the median ±
interquartile from six independent mice per group.
(B, E‒G) Eight-week-old female NOD mice were treated with butyrate and 3 days later CRAMP production was analyzed in the short-term islet culture (B), the
subtypes of pancreatic macrophage (E), or the ALDH activity in pancreatic DCs (F); pancreatic Treg cell frequency was analyzed 8 days after butyrate treatment
(G). Data are representative or are the median ± interquartile range from five or six independent experiments with two pooled mice per group in each experiment.
(C and D) Islets were isolated from 8-week-old femalemice and treated in vitro with SCFAs and/or pertussis toxin (PTX), andCRAMPproductionwas evaluated by
ELISA. In (D), islets from female NOD mice were used. Data are the median ± interquartile range from six independent experiments with two pooled mice per
group in each experiment.
(legend continued on next page)
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(Larrick et al., 1995); inhibition of the translocation of NF-kB sub-
units (Mookherjee et al., 2006) or perturbation of the MAPK and
MyD88 pathways (Pinheiro da Silva et al., 2009). In line with our
present results, thehumancathelicidin hasbeenshown to reduce
pro-inflammatory activity of inflammatory macrophages, while
preserving anti-inflammatory activity of regulatory macrophages
in the lungs (Brown et al., 2011). Similar anti-inflammatory effects
have been described for cDCs in a mouse model of allergic con-
tact dermatitis (DiNardoet al., 2007). Together, these results sug-
gest that in case of infection, cathelicidinswould first promote the
innate defense by recruiting innate immune cells and then
dampen the activity of these cells to avoid immunopathologic tis-
sue damage. The pro-inflammatory activity of cathelicidins has
been particularly described in autoinflammatory and autoim-
mune contexts such as atherosclerosis, psoriasis, systemic
lupus erythematous, and initiation of autoimmune diabetes (Kah-
lenberg and Kaplan, 2013). In these contexts, the proinflamma-
tory activity of cathelicidins is linked to their ability to bind extra-
cellular self-nucleic acids and to potentiate the activation of type I
IFN secreting-pDCs via TLR7/9. In these diseases, cathelicidins
are produced by activated neutrophils producing neutrophil
extracellular traps (NETs) with major consequences for the func-
tion of cathelicidins (Pinegin et al., 2015). First, their local concen-
tration in the tissue would be high since immature neutrophils
store high amounts of cathelicidins in their granules and release
them after activation. It has been estimated that one hundred
thousand activated neutrophils secrete around 10 ng ml1 of
cathelicidin in 15 min culture (Jann et al., 2009), whereas we
observed in the present study that similar number of islet cells
secrete around 80 pg ml1 of cathelicidin in overnight culture.
Second, we suggest that, as many proteins of the NETs (Wang
et al., 2009), cathelicidins produced by activated neutrophils
might becitrullinated,while cathelicidins expressedbyendocrine
cells were not and it has been shown that this post-translation
modification suppresses the immunoregulatory properties of
cathelicidins (Kilsga˚rd et al., 2012; Koziel et al., 2014). Collec-
tively, these data support that the diverse cellular source and
associated post-translational modifications of cathelicidins
might explain their opposite roles in inflammation. This hypothe-
sis might reconcile our previous (Diana et al., 2013) and present
studies, demonstrating two opposing roles of cathelicidins in
different stages of development of autoimmune diabetes. Citrul-
linated cathelicidin produced by NETotic neutrophils in young
NOD mice would initiate the disease via the activation of pDCs,
while non-modified cathelicidin produced by endocrine cells in
adult mice would regulate infiltrating immune cells and prevents
the development of the disease.
In thepresent study,weshow that theproductionofCRAMPby
endocrine cells is dependent of SCFAs and their associated re-
ceptors GPR41 and GPR43. These receptors have been shown
to be expressed by b-cells (Bahar Halpern et al., 2012) but their
functions on these cells remained unclear. In other inflammatory
context, stimulation of GPR43 by SCFAs was required for the(H) Islets were isolated from female NOD mice treated with butyrate, or vehicle (d
before staining for TCR-b and CD8 and IFN-g. Data are the frequency of IFN-g
interquartile range from four independent experiments with two independent mic
(I) Female 8-week-old NOD mice were treated twice a week with butyrate and inc
***p < 0.001.normal resolution of inflammation, because GPR43-deficient
mice showed exacerbated or unresolving inflammation inmodels
of colitis, arthritis, and asthma (Maslowski et al., 2009). The anti-
inflammatory role of SCFAs has been also described in allergic
inflammation in the lung (Trompette et al., 2014) and in colitis
(Smith et al., 2013). Additionally, butyrate is also anti-inflamma-
tory via its ability to promote differentiation of colonic and periph-
eral Treg cells (Arpaia et al., 2013; Furusawa et al., 2013).
Here we also demonstrates that the gut microbiota via SCFAs
directly shape the immune environment in the pancreas regu-
lating autoimmune diabetes. A role for the gut microbiota has
been proposed in various autoimmune diseases including T1D
via the modulation of both the function of the colonic epithelium
and the gut immune system (Mathis and Benoist, 2012). The gut
microbiota of T1D animal models and T1D patients is alteredwith
a lower proportion of butyrate-producing bacteria species (i.e.,
Firmicutes Clostridium) than controls (de Goffau et al., 2013;
Giongo et al., 2011; Roesch et al., 2009). Furthermore, the partial
protection against autoimmune diabetes observed in the male
NOD mice compared to the female counterpart has been asso-
ciated with difference in the composition of their gut microbiota
(Markle et al., 2013; Yurkovetskiy et al., 2013). In these studies,
the transfer of gut microbiota from male to female NOD
mice confers protection against diabetes that is attributed to
hormonal-dependent mechanism. However, male microbiota
transferred to female also results in an increased proportion of
butyrate-producing bacteria in the gut of female NODmice. Alto-
gether, these data support that the gut microbiota might regulate
the development of autoimmune diabetes via hormonal-depen-
dent and SCFA-dependent complementary pathways.
Diet plays a crucial role in the production of SCFAs in the gut
by shaping the composition of the microbiota and by being the
fuel for the production of SCFAs from dietary fibers (Thorburn
et al., 2014). T1D is a complex autoimmune disease under poly-
genic control, but its development also depends on various envi-
ronmental factors such as microbes, pollutants, and diet (Bach
and Chatenoud, 2012). Thus, it is tempting to speculate that
the rising incidence of T1D and other autoimmune diseases
observed in western countriesmay be associatedwith nutritional
changes that have appeared during the last century. More
importantly is the reduced consumption of fruit and vegetables
rich in fibers necessary for themaintenance of a ‘‘healthy’’ micro-
biota. In conclusion, our study suggests that the simple manipu-
lation of our gut microbiota via the use of specific diet might
directly impact on the production of AMPs in peripheral tissues
via SCFAs, thus maintaining the local immune homeostasis
and prevent the development of autoimmune diseases.EXPERIMENTAL PROCEDURES
Mice and Treatments
Female and male BALB/c, C57BL/6J, C57BL/6J Cnlp/, NOD, and NOD
scid mice between 8 and 10 weeks of age were used, bred, and houseday 10). After 8-day culture, cells were stimulated with IGRP206–214-loaded DCs,
+ cells among CD8+ T cell population and are representative or the median ±
e per group in each experiment.
idence of diabetes was followed, n = 12 mice per group. *p < 0.05, **p < 0.01,
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Figure 7. Gut Microbiota Modulates CRAMP-Production in the Pancreatic Islets
(A and B) Six-week-old male NODmice were treated for 7 days with antibiotic cocktail (ABX) or 6-week-old female NODmice were transferred with female or male
gut microbiota from various mouse strains (/). Islets were isolated and cultured overnight to measure CRAMP secretion by ELISA (A) or macrophage sub-
populations in the islets was directly analyzed by flow cytometry (B). Data are representative or are the median ± interquartile range from 5 or 6 independent
experiments with 2 pooled mice per group in each experiment.
(C) Six-week-old male NOD mice were treated for 7 days with antibiotic cocktail (ABX) and then with CRAMP (100 mg/mouse). Islets were isolated and
macrophage sub-populations in the islets was directly analyzed by flow cytometry. Data are representative or are the median ± interquartile range from five
independent experiments with two pooled mice per group in each experiment.
(D) Six-week-old male NOD mice were treated for 7 days with antibiotic cocktail (ABX) and incidence of diabetes was followed, n = 10 mice per group.
(E) Six-week-old female NOD mice were transferred with female or male gut microbiota from 8-week-old NOD mice and incidence of diabetes was followed,
n = 10 mice per group. *p < 0.05, **p < 0.01.in specific pathogen-free conditions. C57BL/6J Cnlp/ mice were pur-
chased from the Jackson Laboratory before housing and breeding in our
laboratory. The C57BL/6J Cnlp/ strain was maintained as heterozygote
animals to provide genetically matched WT and KO littermate mice.314 Immunity 43, 304–317, August 18, 2015 ª2015 Elsevier Inc.CRAMP1–39, scrambled (s) CRAMP1–39, LL-37, and sLL-37 (all from Innova-
gen) were administrated i.p. at the dose of 100 mg diluted in 200 ml of
vehicle (PBS-1% H2O). See Supplemental Experimental Procedures for com-
plete description of the treatments used. All animal experimental protocols
were approved by the ethic committee for animal experimentation
(CEEA34.JD.046.12).
Spontaneous Diabetes Incidence
Eight-week-old NOD female mice received two injections of CRAMP (2 3
100 mg) during one week or two injections of sodium butyrate (2 3 1 mg) or
two injections of vehicle (PBS-1% H2O). Overt diabetes was defined as two
positive urine glucose tests, confirmed by a glycemia > 200 mg dL1. Glukot-
est kit was purchased from Roche. Glucose tests and measure of glycemia
were performed in a blind fashion.
Preparation of Pancreatic Islets
Pancreata were perfused with a solution of collagenase P in HBSS-1%HEPES
(0.75 mg mL1, Roche), then dissected free from surrounding tissues. Pan-
creata were digested at 37C for 8 min. Digestion was stopped by adding
HBSS-10% FCS-1% EDTA followed by extensive washes. For flow cytometry
analysis, islets were purified on a discontinuous Ficoll gradient (Sigma-
Aldrich) and then cells were released from the islets by incubation at 37C
for 6 min in non-enzymatic cell dissociation solution (Sigma-Aldrich). For islet
cultures, to avoid potential contamination by exocrine tissue, islets were puri-
fied by handpicking in three consecutive baths of HBSS-10% FCS supple-
mented with 1% DNase 1.
Flow Cytometry
Single cell suspensions were prepared from various tissues and were stained
for 30min at 4C after FcgRII/III blocking with anti-CD16/CD32 monoclonal
antibody (mAb). Staining buffer was PBS containing 2% FCS, 0.5% EDTA,
and 0.1% sodium azide. See Supplemental Experimental Procedures for com-
plete description of the antibodies used. For cytokine expression by macro-
phages and DCs, cell suspension was incubated 5 hr at 37C with LPS
(1 mg ml1, Sigma-Aldrich) in the presence of a protein transport inhibitor
cocktail (eBioscience). For ALDH activity measurement, cells were stained us-
ing the ALDEFLUOR kit according to the manufacturer’s protocol (Stemcell).
For measurement of diabetogenic CD8+ T cell response, isolated cells were
stimulated for 4 hr at 37C with bone-marrow derived DCs loaded with
IGRP206–214 peptide in presence of protein transport inhibitor cocktail. For reg-
ulatory T cell detection, cells were surface stained with anti-TCRb, -CD4 (BD,
RM4-5), fixed and then stained for Foxp3 expression, utilizing the Foxp3 stain-
ing kit (eBioscience). In all experiments dead cells were excluded using Fixable
Viability Dye (eBioscience). Stained cells were analyzed on a Becton Dickinson
Fortessa flow cytometer.
Western Blot Analysis of CRAMP
After overnight culture islet-free supernatant and islets were recovered. Islets
were lysed with 60% acetonitrile in 1% trifluoroacetic acid (TFA) overnight at
4C. On the second day, islet lysates in acetonitrile were lyophilized and the
dried cellular components were dissolved in H2Owith 0.1% TFA. Polypeptides
were then enriched from acidified islet supernatants or islet lysates using
reverse-phase chromatography (OASIS cartridge, Waters). Western blot
analysis of CRAMP was performed in the islet supernatant (secreted) and in
the islet lysates (cellular), synthesized CRAMP peptide was used as control.
See Supplemental Experimental Procedures for complete description of the
method used.
CRAMP Measurement by ELISA
One hundred handpicked pancreatic islets were cultured in 200 ml of a solution
of DMEM, 10% FBS, 1% penicillin/streptomycin overnight, and CRAMP con-
centration were analyzed using themouse CRAMP ELISA kit (Mybiosource). In
some experiments, sodium butyrate (500 mg ml1) and/or pertussis toxin
(100 ng ml1, Sigma-Aldrich) were added to the islet culture.
Cytology
Handpicked pancreatic islets were seeded on SuperFrost Gold Plus micro-
scope slide by cytospin. Then, islets were fixed, permeabilized, and after
stained with anti-insulin pAb (Abcam), anti-glucagon mAb (Abcam) and anti-
CRAMP pAb or anti-LL-37 pAb (Innovagen), overnight at 4C. After
washing, second-step reagents were applied: anti-guinea pig-AlexaFluor488
(insulin), anti-mouse-Alexa647 (glucagon), and anti-rabbit-AlexaFluor555pAbs (CRAMP and LL-37) (Invitrogen). Nucleuses were stained with DAPI.
Image acquisition was performed on Necker Institute Imaging Facility using
a Leica SP8 confocal microscope.
In Vitro Treg Cell Induction
All cells were magnetically isolated using MACS cell separation system (Milte-
nyi). CD62L+ CD4+ CD25 BDC2.5 T cells (43 104 cells per well) from spleno-
cytes of BDC2.5 TCR transgenic NOD mice were incubated with 2 3 103
myeloid cells (CD11b+) obtained from pancreatic islets of NOD mice treated
with CRAMP or vehicle. Culture were performed for 4 days in complete
IMDM with 5 ng ml1 recombinant human IL-2 (R&D), 1 ng ml1 recombinant
mouse TGF-b (R&D) and 20 ng ml1 of peptide 1040-51, a mimotope of
BDC2.5 T cells. In some conditions retinoic acid inhibitor LE135 (1 mM, Santa
Cruz) was added to the culture.
SCFA Measurement by Gas Chromatography–Mass Spectrometry
The short-chain fatty acids (SCFAs)—acetate, propionate and butyrate—
present in the fecal content of male and female NOD mice were analyzed by
GC/MS. See Supplemental Experimental Procedures for complete description
of the method used.
Statistical Analysis
Diabetes incidence was plotted according to the Kaplan-Meier method. Inci-
dences between each group were compared with the log-rank test. Reported
values are median ± interquartile range as indicated. Comparison between
each group was performed using the non-parametric Mann-Whitney U-test.
p values < 0.05 were considered statistically significant. All data were analyzed
using GraphPad Prism v5 software.
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